JP2023532248A - 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体 - Google Patents

免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体 Download PDF

Info

Publication number
JP2023532248A
JP2023532248A JP2022579851A JP2022579851A JP2023532248A JP 2023532248 A JP2023532248 A JP 2023532248A JP 2022579851 A JP2022579851 A JP 2022579851A JP 2022579851 A JP2022579851 A JP 2022579851A JP 2023532248 A JP2023532248 A JP 2023532248A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
antibody
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022579851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532248A5 (https=
Inventor
スイ、ジャンフア
ヤン、フアン
ジャオ、リンリン
ウエイ、ジィゾン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huahui Health Ltd
Original Assignee
Huahui Health Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huahui Health Ltd filed Critical Huahui Health Ltd
Publication of JP2023532248A publication Critical patent/JP2023532248A/ja
Publication of JP2023532248A5 publication Critical patent/JP2023532248A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022579851A 2020-06-24 2021-06-23 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体 Pending JP2023532248A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/098133 2020-06-24
PCT/CN2020/098133 WO2021258337A1 (en) 2020-06-24 2020-06-24 Human monoclonal antibodies against tigit for immune related diseases
PCT/CN2021/101901 WO2021259335A1 (en) 2020-06-24 2021-06-23 Human monoclonal antibodies against tigit for immune related diseases

Publications (2)

Publication Number Publication Date
JP2023532248A true JP2023532248A (ja) 2023-07-27
JP2023532248A5 JP2023532248A5 (https=) 2024-06-06

Family

ID=79281998

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579851A Pending JP2023532248A (ja) 2020-06-24 2021-06-23 免疫関連疾患のためのｔｉｇｉｔに対するヒトモノクローナル抗体

Country Status (5)

Country Link
US (1) US12606619B2 (https=)
EP (1) EP4172209A4 (https=)
JP (1) JP2023532248A (https=)
CN (1) CN116670286A (https=)
WO (2) WO2021258337A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4320160A1 (en) * 2021-04-09 2024-02-14 Seagen Inc. Methods of treating cancer with anti-tigit antibodies
CN115043910B (zh) * 2022-03-25 2023-04-07 湖南中晟全肽生化有限公司 抑制tigit与cd155结合的多肽及其应用
WO2025255297A1 (en) * 2024-06-05 2025-12-11 Agilent Technologies, Inc. Anti-human tigit antibodies for in vitro diagnostics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4733C1 (ro) 2014-08-19 2021-07-31 Merck Sharp & Dohme Corp Anticorpi anti-TIGIT
TWI715587B (zh) * 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
CN108290936B (zh) * 2015-08-14 2022-07-12 默沙东公司 抗tigit抗体
EP3589313A4 (en) * 2017-02-28 2021-05-19 Seagen Inc. ANTI-TIGITE ANTIBODY
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CN109384846B (zh) * 2018-09-25 2020-03-03 合肥瑞达免疫药物研究所有限公司 能够结合tigit的抗体或其抗原结合片段及用途
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN109734806B (zh) 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KUMAR, SANDEEP ET AL.: "Development and functional characterization of COM902, a novel therapeutic antibody targeting the im", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 5(Suppl 2):87, P344, JPN6025022640, 2017, ISSN: 0005697201 *

Also Published As

Publication number Publication date
US12606619B2 (en) 2026-04-21
CN116670286A (zh) 2023-08-29
WO2021259335A1 (en) 2021-12-30
WO2021258337A1 (en) 2021-12-30
US20230272067A1 (en) 2023-08-31
EP4172209A1 (en) 2023-05-03
EP4172209A4 (en) 2025-01-15

Similar Documents

Publication Publication Date Title
US20240409655A1 (en) Anti-ox40 antibodies and methods of use
US10493148B2 (en) PD-1 agonist antibodies and uses thereof
JP6526189B2 (ja) 抗ｐｄ−ｌ１抗体並びにその治療及び診断のための使用
JP7638935B2 (ja) 抗ｃｃｒ８抗体
KR20180028519A (ko) 항-TfR 항체 및 증식성 및 염증성 장애의 치료에서의 그의 용도
CN113164781A (zh) 拮抗性cd40单克隆抗体及其用途
CN103596982A (zh) 治疗性抗体
JP7843824B2 (ja) 抗体および使用方法
CN112739422B (zh) Cd200r激动剂抗体及其用途
US12606619B2 (en) Human monoclonal antibodies against TIGIT for immune related diseases
US20240228649A9 (en) Crtam antibodies and methods of treating cancer
WO2015136471A1 (en) Anti-laminin4 antibodies specific for lg1-3
KR20250044359A (ko) 항-ccr8 항체 및 사용 방법
CN114746446A (zh) 使用抗ox40抗体与抗tigit抗体组合治疗癌症的方法
TW202307004A (zh) 抗ｃｅａ抗體及使用方法
CN114728063B (zh) 用抗ox40抗体和多重激酶抑制剂治疗癌症
CN114641500B (zh) 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
HK40096718A (zh) 用於免疫相关疾病的人抗tigit单克隆抗体
CN119698295A (zh) 使用抗tigit抗体的癌症治疗方法
HK40076665A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
HK40074321A (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240529

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250910

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250930